Survivorship: cognitive function, version 1.2014

J Natl Compr Canc Netw. 2014 Jul;12(7):976-86. doi: 10.6004/jnccn.2014.0094.

Abstract

Cognitive impairment is a common complaint among cancer survivors and may be a consequence of the tumors themselves or direct effects of cancer-related treatment (eg, chemotherapy, endocrine therapy, radiation). For some survivors, symptoms persist over the long term and, when more severe, can impact quality of life and function. This section of the NCCN Guidelines for Survivorship provides assessment, evaluation, and management recommendations for cognitive dysfunction in survivors. Nonpharmacologic interventions (eg, instruction in coping strategies; management of distress, pain, sleep disturbances, and fatigue; occupational therapy) are recommended, with pharmacologic interventions as a last line of therapy in survivors for whom other interventions have been insufficient.

Publication types

  • Guideline

MeSH terms

  • Adaptation, Psychological*
  • Benzhydryl Compounds / therapeutic use
  • Brain Neoplasms / mortality
  • Brain Neoplasms / pathology*
  • Central Nervous System Stimulants / therapeutic use
  • Cognition Disorders / drug therapy
  • Cognition Disorders / therapy*
  • Fatigue / therapy
  • Humans
  • Methylphenidate / therapeutic use
  • Modafinil
  • Occupational Therapy
  • Pain Management*
  • Quality of Life*
  • Sleep Wake Disorders / therapy
  • Survival Rate
  • Treatment Outcome
  • Wakefulness-Promoting Agents / therapeutic use

Substances

  • Benzhydryl Compounds
  • Central Nervous System Stimulants
  • Wakefulness-Promoting Agents
  • Methylphenidate
  • Modafinil